Long non‑coding RNA miR155HG silencing restrains ovarian cancer progression by targeting the microRNA‑155‑5p/tyrosinase‑related protein 1 axis

Wen,Aiping; Luo,Le; Du,Chengchao; Luo,Xin

doi:10.3892/etm.2021.10672

Long non‑coding RNA miR155HG silencing restrains ovarian cancer progression by targeting the microRNA‑155‑5p/tyrosinase‑related protein 1 axis

Authors:
- Aiping Wen
- Le Luo
- Chengchao Du
- Xin Luo
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China, Sichuan Key Laboratory of Medical Imaging, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China, Department of Gynecology and Obstetrics, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510630, P.R. China
Published online on: August 31, 2021 https://doi.org/10.3892/etm.2021.10672
Article Number: 1237
Copyright: © Wen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer (OC) is the third commonest gynecological malignancy worldwide. The long non‑coding (lnc)RNA microRNA (miR)155HG functions as an oncogene in different human cancers. However, the function and molecular mechanism of miR155HG in OC remain elusive. The present study indicated that the expression levels of miR155HG and tyrosinase‑related protein 1 (TYRP1) were significantly increased, whereas that of miR155‑5p was decreased in OC tissues and cells, as detected by real‑time quantitative polymerase chain reaction. It was demonstrated that knockdown of miR155HG markedly inhibited OC cell viability, migration and invasion while promoting apoptosis, as indicated by 3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑diphenyltetrazolium bromide, wound healing, Transwell and western blot assays. Mechanistically, it was revealed that miR155HG and TYRP1 were both targeted by miR‑155‑5p with complementary binding sites in the 3' untranslated region. A dual‑luciferase reporter assay was used to confirm the targeting relationship between miR155HG, miR‑155‑5p and TYRP1. In addition, the interaction between miR155HG and miR‑155‑5p was further demonstrated by radioimmunoprecipitation and pull‑down assays. In addition, feedback approaches determined that miR‑155‑5p inhibition or TYRP1 overexpression markedly reversed the inhibitory effects of miR155HG knockdown on OC cell viability, migration and invasion as well as weakened the promotive effect of miR155HG knockdown on OC cell apoptosis. Thus, miR155HG silencing inhibited the malignant biological behavior of OC cells by targeting the miR‑155‑5p/TYRP1 axis. The present study provides novel insights into the underlying mechanism of OC progression.

View Figures

View References

1	Nash Z and Menon U: Ovarian cancer screening: Current status and future directions. Best Pract Res Clin Obstet Gynaecol. 65:32–45. 2020.PubMed/NCBI View Article : Google Scholar
2	Nimmagadda S and Penet MF: Ovarian cancer targeted theranostics. Front Oncol. 9(1537)2020.PubMed/NCBI View Article : Google Scholar
3	Chandra A, Pius C, Nabeel M, Nair M, Vishwanatha JK, Ahmad S and Basha R: Ovarian cancer: Current status and strategies for improving therapeutic outcomes. Cancer Med. 8:7018–7031. 2019.PubMed/NCBI View Article : Google Scholar
4	Stewart C, Ralyea C and Lockwood S: Ovarian cancer: An integrated review. Semin Oncol Nurs. 35:151–156. 2019.PubMed/NCBI View Article : Google Scholar
5	Chen Y, Du H, Bao L and Liu W: LncRNA PVT1 promotes ovarian cancer progression by silencing miR-214. Cancer Biol Med. 15:238–250. 2018.PubMed/NCBI View Article : Google Scholar
6	Du W, Feng Z and Sun Q: LncRNA LINC00319 accelerates ovarian cancer progression through miR-423-5p/NACC1 pathway. Biochem Biophys Res Commun. 507:198–202. 2018.PubMed/NCBI View Article : Google Scholar
7	Kong FR, Lv YH, Yao HM, Zhang HY, Zhou Y and Liu SE: LncRNA PCAT6 promotes occurrence and development of ovarian cancer by inhibiting PTEN. Eur Rev Med Pharmacol Sci. 23:8230–8238. 2019.PubMed/NCBI View Article : Google Scholar
8	Qin Y, Liu X, Pan L, Zhou R and Zhang X: Long noncoding RNA MIR155HG facilitates pancreatic cancer progression through negative regulation of miR-802. J Cell Biochem. 120:17926–17934. 2019.PubMed/NCBI View Article : Google Scholar
9	Wu W, Yu T, Wu Y, Tian W, Zhang J and Wang Y: The miR155HG/miR-185/ANXA2 loop contributes to glioblastoma growth and progression. J Exp Clin Cancer Res. 38(133)2019.PubMed/NCBI View Article : Google Scholar
10	Li N and Zhan X: Identification of clinical trait-related lncRNA and mRNA biomarkers with weighted gene co-expression network analysis as useful tool for personalized medicine in ovarian cancer. EPMA J. 10:273–290. 2019.PubMed/NCBI View Article : Google Scholar
11	Xiang G and Cheng Y: miR-126-3p inhibits ovarian cancer proliferation and invasion via targeting PLXNB2. Reprod Biol. 18:218–224. 2018.PubMed/NCBI View Article : Google Scholar
12	Lu J, Wang L, Chen W, Wang Y, Zhen S, Chen H, Cheng J, Zhou Y, Li X and Zhao L: miR-603 targeted hexokinase-2 to inhibit the malignancy of ovarian cancer cells. Arch Biochem Biophys. 661:1–9. 2019.PubMed/NCBI View Article : Google Scholar
13	Duan Y, Dong Y, Dang R, Hu Z, Yang Y, Hu Y and Cheng J: MiR-122 inhibits epithelial mesenchymal transition by regulating P4HA1 in ovarian cancer cells. Cell Biol Int. 42:1564–1574. 2018.PubMed/NCBI View Article : Google Scholar
14	Li S, Zhang T, Zhou X, Du Z, Chen F, Luo J and Liu Q: The tumor suppressor role of miR-155-5p in gastric cancer. Oncol Lett. 16:2709–2714. 2018.PubMed/NCBI View Article : Google Scholar
15	Luo X, Dong J, He X, Shen L, Long C, Liu F, Liu X, Lin T, He D and Wei G: MiR-155-5p exerts tumor-suppressing functions in wilms tumor by targeting IGF2 via the PI3K signaling pathway. Biomed Pharmacother. 125(109880)2020.PubMed/NCBI View Article : Google Scholar
16	Ysrafil Y, Astuti I, Anwar SL, Martien R, Sumadi FAN, Wardhana T and Haryana SM: MicroRNA-155-5p diminishes in vitro ovarian cancer cell viability by targeting HIF1α expression. Adv Pharm Bull. 10:630–637. 2020.PubMed/NCBI View Article : Google Scholar
17	Lai X, Wichers HJ, Soler-Lopez M and Dijkstra BW: Structure and function of human tyrosinase and tyrosinase-related proteins. Chemistry. 24:47–55. 2018.PubMed/NCBI View Article : Google Scholar
18	Wang-Rodriguez J, Urquidi V, Rivard A and Goodison S: Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status. Breast Cancer Res. 5(9)2003.PubMed/NCBI View Article : Google Scholar
19	Udono T, Takahashi K, Yasumoto K, Yoshizawa M, Takeda K, Abe T, Tamai M and Shibahara S: Expression of tyrosinase-related protein 2/DOPAchrome tautomerase in the retinoblastoma. Exp Eye Res. 72:225–234. 2001.PubMed/NCBI View Article : Google Scholar
20	El Hajj P, Journe F, Wiedig M, Laios I, Salès F, Galibert MD, Van Kempen LC, Spatz A, Badran B, Larsimont D, et al: Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients. Br J Cancer. 108:1641–1647. 2013.PubMed/NCBI View Article : Google Scholar
21	Hsu YL, Chen YJ, Chang WA, Jian SF, Fan HL, Wang JY and Kuo PL: Interaction between tumor-associated dendritic cells and colon cancer cells contributes to tumor progression via CXCL1. Int J Mol Sci. 19(2427)2018.PubMed/NCBI View Article : Google Scholar
22	El Hajj P, Gilot D, Migault M, Theunis A, van Kempen LC, Salés F, Fayyad-Kazan H, Badran B, Larsimont D, Awada A, et al: SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma. Br J Cancer. 113:91–98. 2015.PubMed/NCBI View Article : Google Scholar
23	Choi JH and Ro JY: The 2020 WHO classification of tumors of soft tissue: Selected changes and new entities. Adv Anat Pathol. 28:44–58. 2021.PubMed/NCBI View Article : Google Scholar
24	Cui W, Meng W, Zhao L, Cao H, Chi W and Wang B: TGF-β-induced long non-coding RNA MIR155HG promotes the progression and EMT of laryngeal squamous cell carcinoma by regulating the miR-155-5p/SOX10 axis. Int J Oncol. 54:2005–2018. 2019.PubMed/NCBI View Article : Google Scholar
25	Li N, Liu Y and Cai J: LncRNA miR155HG regulates M1/M2 macrophage polarization in chronic obstructive pulmonary disease. Biomed Pharmacother. 117(109015)2019.PubMed/NCBI View Article : Google Scholar
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
27	Javadi S, Ganeshan DM, Qayyum A, Iyer RB and Bhosale P: Ovarian cancer, the revised FIGO staging system, and the role of imaging. AJR AM J Roentgenol. 206:1351–1360. 2016.PubMed/NCBI View Article : Google Scholar
28	Liang H, Yu T, Han Y, Jiang H, Wang C, You T, Zhao X, Shan H, Yang R, Yang L, et al: LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression. Mol Cancer. 17(119)2018.PubMed/NCBI View Article : Google Scholar
29	Wang X, Yang B, She Y and Ye Y: The lncRNA TP73-AS1 promotes ovarian cancer cell proliferation and metastasis via modulation of MMP2 and MMP9. J Cell Biochem. 119:7790–7799. 2018.PubMed/NCBI View Article : Google Scholar
30	Lai XJ and Cheng HF: LncRNA colon cancer-associated transcript 1 (CCAT1) promotes proliferation and metastasis of ovarian cancer via miR-1290. Eur Rev Med Pharmacol Sci. 22:322–328. 2018.PubMed/NCBI View Article : Google Scholar
31	Zou T, Wang PL, Gao Y and Liang WT: Long noncoding RNA HOTTIP is a significant indicator of ovarian cancer prognosis and enhances cell proliferation and invasion. Cancer Biomark. 25:133–139. 2019.PubMed/NCBI View Article : Google Scholar
32	He X, Sheng J, Yu W, Wang K, Zhu S and Liu Q: LncRNA MIR155HG promotes temozolomide resistance by activating the wnt/β-catenin pathway via binding to PTBP1 in glioma. Cell Mol Neurobiol. 11:1271–1284. 2020.PubMed/NCBI View Article : Google Scholar
33	Ren XY, Han YD and Lin Q: Long non-coding RNA MIR155HG knockdown suppresses cell proliferation, migration and invasion in NSCLC by upregulating TP53INP1 directly targeted by miR-155-3p and miR-155-5p. Eur Rev Med Pharmacol Sci. 24:4822–4835. 2020.PubMed/NCBI View Article : Google Scholar
34	Fu X, Zhang L, Dan L, Wang K and Xu Y: LncRNA EWSAT1 promotes ovarian cancer progression through targeting miR-330-5p expression. Am J Transl Res. 9:4094–4103. 2017.PubMed/NCBI
35	Mu Y, Li N and Cui YL: The lncRNA CCAT1 upregulates TGFβR1 via sponging miR-490-3p to promote TGFβ1-induced EMT of ovarian cancer cells. Cancer Cell Int. 18(145)2018.PubMed/NCBI View Article : Google Scholar
36	Tong L, Ao Y, Zhang H, Wang K, Wang Y and Ma Q: Long noncoding RNA NORAD is upregulated in epithelial ovarian cancer and its downregulation suppressed cancer cell functions by competing with miR-155-5p. Cancer Med. 8:4782–4791. 2019.PubMed/NCBI View Article : Google Scholar
37	Wu X, Wang Y, Yu T, Nie E, Hu Q, Wu W, Zhi T, Jiang K, Wang X, Lu X, et al: Blocking MIR155HG/miR-155 axis inhibits mesenchymal transition in glioma. Neuro Oncol. 19:1195–1205. 2017.PubMed/NCBI View Article : Google Scholar
38	Tao M, Zhou Y, Jin Y and Pu J: Blocking lncRNA MIR155HG/miR-155-5p/-3p inhibits proliferation, invasion and migration of clear cell renal cell carcinoma. Pathol Res Pract. 216(152803)2020.PubMed/NCBI View Article : Google Scholar
39	Zhao XS, Han B, Zhao JX, Tao N and Dong CY: miR-155-5p affects Wilms' tumor cell proliferation and apoptosis via targeting CREB1. Eur Rev Med Pharmacol Sci. 23:1030–1037. 2019.PubMed/NCBI View Article : Google Scholar
40	Chen L, Yang X, Zhao J, Xiong M, Almaraihah R, Chen Z and Hou T: Circ_0008532 promotes bladder cancer progression by regulation of the miR-155-5p/miR-330-5p/MTGR1 axis. J Exp Clin Cancer Res. 39(94)2020.PubMed/NCBI View Article : Google Scholar
41	Journe F, Id Boufker H, Van Kempen L, Galibert MD, Wiedig M, Salès F, Theunis A, Nonclercq D, Frau A, Laurent G, et al: TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome. Br J Cancer. 105:1726–1732. 2011.PubMed/NCBI View Article : Google Scholar
42	Liu G, Khong HT, Wheeler CJ, Yu JS, Black KL and Ying H: Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma. J Immunother. 26:301–312. 2003.PubMed/NCBI View Article : Google Scholar
43	Gilot D, Migault M, Bachelot L, Journé F, Rogiers A, Donnou-Fournet E, Mogha A, Mouchet N, Pinel-Marie ML, Mari B, et al: A non-coding function of TYRP1 mRNA promotes melanoma growth. Nat Cell Biol. 19:1348–1357. 2017.PubMed/NCBI View Article : Google Scholar